The FDA announced it will begin a pilot effort to let reviewers access clinical trial data in real time as it flows in. The initiative is intended to accelerate benefit-risk assessment during ongoing studies rather than after data lock. AstraZeneca and Amgen are already participating in the pilot, according to the agency. Trials highlighted include an AstraZeneca Phase 2 lymphoma study conducted at MD Anderson and the University of Pennsylvania, and an Amgen Phase 1b trial in small cell lung cancer. The FDA also opened a public input process tied to a potential broader program involving companies using AI for safety monitoring, dose selection, safety signal detection, and patient recruitment. A real-time data platform built by Paradigm Health will support the participating trials.